Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX2853 and Trametinib in Advanced Uveal Melanoma
NCT05677373Phase 2Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of PLX2853 in Uveal melanoma (UM), sponsored by Cancer and Leukemia Group B. Planned start Jan 2023; status: withdrawn.
02
Drugs
PLX2853
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05677373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677373.